WaveMan
WaveMan · Company
BLCO · Bausch & Lomb Corp
> Search tickers & screens ⌘K
LIVE
← All companies

BLCO Bausch & Lomb (BLCO) Insider Trading, Ownership & Congress Trades

Medical Devices · Ophthalmic goods · CIK 0001860742
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter

What the filings say about BLCO

Insiders, 180 days
-$1.2M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.3M
4 notices

Bausch & Lomb insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Bausch & Lomb Corp insiders sold a net $1.2M of stock across 17 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Munsch Frederick
SVP, Controller and CAO
SELL
2026-08-12 SECtraded 2026-08-10
52,900
$887.7K
+3.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 115.4% of the 45,831 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Controller and CAO Munsch Frederick sold about $887.7K of BLCO on Aug 10, 2026, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
VON ESCHENBACH ANDREW C.
Director
SELL
2026-08-10 SECtraded 2026-08-07
6,059
$100.5K
+4.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Aug 6, 2026.
  • +1.9% median (+1.9% mean) 90-day return after 2 previous buys.
  • The trade is 9.5% of the 63,733 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director VON ESCHENBACH ANDREW C. sold about $100.5K of BLCO on Aug 7, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
VON ESCHENBACH ANDREW C.
Director
SELL
2026-08-10 SECtraded 2026-08-06
12,500
$206.2K
+4.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Feb 27, 2026.
  • +1.9% median (+1.9% mean) 90-day return after 2 previous buys.
  • The trade is 17.9% of the 69,792 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director VON ESCHENBACH ANDREW C. sold about $206.2K of BLCO on Aug 6, 2026, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
Bailey A Robert D
EVP & Chief Legal Officer
BUY
2026-03-10 SECtraded 2026-03-06
14,600
$250.4K
+0.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.3% of the 231,890 shares held after it.
  • 8 other insiders bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Legal Officer Bailey A Robert D bought about $250.4K of BLCO on Mar 6, 2026; 8 other insiders bought within 30 days and 49 funds added in the latest 13F quarter.
Eldessouky Sam
EVP and CFO
BUY
2026-03-10 SECtraded 2026-03-06
4,000
$68.5K
+0.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.0% of the 403,130 shares held after it.
  • 8 other insiders bought within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and CFO Eldessouky Sam bought about $68.5K of BLCO on Mar 6, 2026; 8 other insiders bought within 30 days and 49 funds added in the latest 13F quarter.
17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 12 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.2M over 180 days
-$1.2M over 90 days
below 63% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
49 funds bought in last quarter
below 58% of Medical Devices
Revenue
+6.5% year over year
below 60% of Medical Devices
Margin
-7.1% net margin
more than 60% of Medical Devices
Buybacks
no share repurchases reported
Short interest
5.5% of the float short (float per yahoo 2026-10-27) · 3.6 days to cover · settled 2026-10-15
below 74% of Medical Devices
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BLCO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.7%12M
-8%+1%+9%+18%2025-102025-122026-022026-042026-062026-082026-10 2026-08-10 · Munsch Frederick sold $887.7K2026-02-23 · COLLIS STEVEN H bought $267.1K2026-03-06 · SAUNDERS BRENT L bought $252.0K2026-03-06 · Bailey A Robert D bought $250.4K2026-08-06 · VON ESCHENBACH ANDREW C. sold $206.2K2026-08-07 · VON ESCHENBACH ANDREW C. sold $100.5K2026-02-27 · VON ESCHENBACH ANDREW C. bought $79.9K2026-03-03 · Ross Thomas W. Sr. bought $79.6K2026-02-20 · ROBERTSON RUSSEL C bought $78.8K2026-03-02 · Alfonso Eduardo bought $77.0K2026-02-19 · Ling Karen bought $71.0K2026-03-06 · Eldessouky Sam bought $68.5K2026-09-28 · Ling Karen filed to sell $75.7K2026-08-10 · Munsch Frederick filed to sell $887.9K2026-08-07 · VON ESCHENBACH ANDREW C. filed to sell $100.4K2026-08-06 · VON ESCHENBACH ANDREW C. filed to sell $206.2K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BLCO: institutional holders (13F)

13F holdings, latest reported quarter
ICAHN CARL C
3,500,000 sh
$58.0M
OAKTREE CAPITAL MANAGEMENT LP
3,441,042 sh
$57.0M
DEUTSCHE BANK AG\
3,423,046 sh
$56.7M
D. E. Shaw & Co., Inc.
3,323,021 sh
$55.0M
Davidson Kempner Capital Management LP
3,158,972 sh
$52.3M

Congress trades in BLCO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BLCO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Ling Karen
Filed 2026-09-28
$75.7K
Munsch Frederick
Filed 2026-08-10
$887.9K
VON ESCHENBACH ANDREW C.
Filed 2026-08-07
$100.4K
VON ESCHENBACH ANDREW C.
Filed 2026-08-06
$206.2K

BLCO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
BALLAST SMALL/MID CAP ETF
$2.4M position · as of 2026-06-30
1.4%
T. Rowe Price Dynamic Credit Fund
$3.4M position · as of 2026-06-30
0.2%
T. Rowe Price Credit Opportunities Fund, Inc.
$791.9K position · as of 2026-05-31
0.2%
T. Rowe Price Institutional High Yield Fund
$3.3M position · as of 2026-05-31
0.2%
T. Rowe Price High Yield Fund, Inc.
$12.4M position · as of 2026-05-31
0.2%
T. Rowe Price Global High Income Bond Fund
$1.0M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
59 registered trials, 7 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
4
Phase 2
1 active
12
Phase 3
0 active
6
Phase 4
1 active
33
Not applicable
4 active
2
Multi-phase
0 active
What changed recently
A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative
2026-10-23 · Not Yet Recruiting → Completed
Phase 2
Revive Toric RWE Study
2026-10-17 · Not Yet Recruiting → Withdrawn · Lens manufacturing has been postponed
,
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In S
2026-10-09 · Active Not Recruiting → Completed
Not applicable
A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
2026-09-11 · Completion moved 2026-08 → 2026-08-05
Phase 1
A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
2026-09-11 · Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Joseph CPapa
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$19.8M
-$4.0M
$4.4M
-22%
-3%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.2M sold by insiders over 180 days, 49 funds added last quarter, $1.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BLCO financials

Revenue growth
+6.5%
XBRL, annual
Net margin
-7.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.3B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$137.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.80x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.09x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-2.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-1.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
+2.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$11.0B
market value at close 2026-10-27 on 2026-07-22 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+2.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$5.1B$4.8B$4.1B$3.8B
Operating income$113.0M$162.0M$130.0M$207.0M
Net income-$360.0M-$317.0M-$260.0M$6.0M
EPS (diluted)-1.02-0.90-0.740.02
Operating cash flow$283.0M$232.0M-$17.0M$345.0M
Cash$383.0M$305.0M$331.0M$354.0M
Long-term debt$5.0B$4.7B$4.5B$2.4B
SEC XBRL, fiscal years, as known on 2026-10-28

BLCO Stock Sonar score 6/7 axes

Find similar shapesCompare

BLCO ranks highest on profitability (68th percentile) and risk and compliance (67th), and lowest on insider conviction (17th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
68
Inputs
  • Return on equity-2.7% · 64 pct, sector of 183
  • Return on assets-1.2% · 67 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed+2.7% · 73 pct, sector of 188
Financial health
41
Inputs
  • Debt to equity0.80x · 24 pct, sector of 159
  • Cash flow to debt0.09x · 58 pct, sector of 150
Growth
40
Inputs
  • Revenue growth, YoY+6.5% · 40 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
17
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.2M · 35 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
23
Inputs
  • Funds adding, latest quarter49 · 42 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$30K · 4 pct, sector of 50
Risk and compliance
67
Inputs
  • Short interest, % of float+5.5% · 43 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.0% · 58 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BLCO filings, in plain words

Are Bausch & Lomb insiders buying or selling BLCO?

In the 180 days to 2026-10-28, Bausch & Lomb insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of BLCO?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.3M of stock; the latest, by Ling Karen, was filed 2026-09-28.

Read the full summary

In the 180 days to 2026-10-28, Bausch & Lomb insiders were net sellers of BLCO, a net $1.2M across purchases and sales reported on Form 4 by 2 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies